AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With ...
AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.
AstraZeneca (AZN) Gets a Buy from Bernstein
In a report released on February 24, Florent Cespedes from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...